(KVUE) Kenvue - Ratings and Ratios

Kenvue Inc. (NYSE:KVUE) is a leading global consumer health company, spun off from Johnson & Johnson in 2022, operating across major markets including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. The company specializes in personal care products, functioning through three distinct business segments: Self Care, Skin Health and Beauty, and Essential Health. Its diverse portfolio includes well-known brands such as Tylenol, Motrin, Neutrogena, Aveeno, Listerine, and Johnsons, catering to a broad range of consumer health needs.

The Self Care segment focuses on over-the-counter medications and health solutions, offering products for pain relief, cough, cold, and allergy treatments, digestive health, and smoking cessation. Key brands include Tylenol, Motrin, Benadryl, and Nicorette, which are trusted for their efficacy in managing common health issues. The Skin Health and Beauty segment provides a wide array of personal care products, including face and body care, hair care, and sun protection, under brands like Neutrogena, Aveeno, and OGX. This segment emphasizes innovation and dermatological expertise, particularly in sun care and natural ingredients. The Essential Health segment covers oral care, baby care, womens health, and wound care, featuring iconic brands such as Listerine, Johnsons, Band-Aid, and Desitin. This segment is known for its trusted, long-standing products that address everyday health and hygiene needs.

Headquartered in Summit, New Jersey, Kenvue Inc. leverages its extensive global reach and brand portfolio to maintain a strong position in the personal care products industry. Its strategic focus on consumer health and wellness positions it as a key player in the global market.

3-Month Forecast: Based on the provided data, Kenvue Inc. (KVUE) is expected to maintain a stable performance in the short term. The stock is currently trading at $23.39, slightly above its 20-day and 50-day moving averages of $22.94 and $22.75, respectively. The 200-day moving average of $21.63 indicates a positive long-term trend. With an average true range (ATR) of 0.65, volatility is moderate, suggesting price fluctuations within a narrow range. The relative strength index (RSI) of 56 indicates the stock is not overbought or oversold, signaling a neutral stance. Fundamental analysis shows a forward P/E ratio of 19.76, suggesting potential undervaluation compared to its current P/E of 42.09. However, the high P/B ratio of 4.51 reflects a premium valuation. The companys return on equity (RoE) of 10.65% indicates decent profitability. Overall, KVUE is expected to trade sideways in the near term, with potential support at $22.50 and resistance at $24.50, influenced by market sentiment and broader economic conditions.